The mutation rate of TP53 (53%, n=1314) was significantly lower in a previous study launched by the Fudan University Shanghai Cancer Center (FUSCC) (4), which also included Chinese patients with both primary and metastasis cancer. This evidence concerns the gene TP53 and cancer.